Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response.


Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
04 2022
Historique:
received: 31 10 2021
revised: 08 02 2022
accepted: 08 03 2022
pubmed: 19 3 2022
medline: 19 4 2022
entrez: 18 3 2022
Statut: ppublish

Résumé

We explored the performance of a whole blood interferon gamma release assay (IGRA) based on the stimulation of SARS-Cov2-specific T cells by purified recombinant proteins. Twenty volunteers vaccinated with BNT162b2 were selected first for T cell response evaluation using an in-house IGRA, a commercial IGRA, and ELISpot showing a S2 > S1 poly-epitopic response. Next, 64 vaccinated and 103 non-vaccinated individuals were tested for humoral and T cell response (IGRA-Spike/-nucleocapsid recombinant proteins). Following the second vaccine injection, humoral (100%) and IGRA-Spike T cell (95.3%) responses took place irrespective of sex, age, and vaccine type. The humoral response declined first, followed by IGRA-Spike T cell response after the second vaccine injection. Altogether, this study confirms the utility of the IGRA-Spike/-nucleocapsid assay to complement serology in COVID19 vaccinated individuals and those who have recovered from SARS-Cov2.

Identifiants

pubmed: 35301104
pii: S1521-6616(22)00060-2
doi: 10.1016/j.clim.2022.108979
pmc: PMC8920083
pii:
doi:

Substances chimiques

Antibodies, Viral 0
COVID-19 Vaccines 0
RNA, Viral 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108979

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Références

J Mol Biol. 2020 May 1;432(10):3309-3325
pubmed: 32320687
Pediatrics. 2009 Mar;123(3):e419-24
pubmed: 19254978
J Infect. 2022 Feb;84(2):248-288
pubmed: 34560135
Cell Rep. 2021 Aug 10;36(6):109518
pubmed: 34358460
J Clin Microbiol. 2021 Sep 20;59(10):e0081121
pubmed: 34232708
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
J Infect. 2021 Sep;83(3):381-412
pubmed: 34147528
Nature. 2021 Sep;597(7875):268-273
pubmed: 34320609
Nat Commun. 2021 Apr 6;12(1):2055
pubmed: 33824342
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33261718
Clin Infect Dis. 2022 Aug 24;75(1):e924-e925
pubmed: 34849639
J Infect Public Health. 2021 Feb;14(2):169-178
pubmed: 33486372
Clin Transl Immunology. 2021 Mar 04;10(3):e1259
pubmed: 33728049
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Clin Infect Dis. 2021 Dec 6;73(11):2000-2008
pubmed: 34134134
J Clin Invest. 2020 Dec 1;130(12):6631-6638
pubmed: 32966269
J Virol Methods. 2021 Dec;298:114295
pubmed: 34555429
Clin Res Cardiol. 2021 Aug;110(8):1142-1149
pubmed: 34241676

Auteurs

Yves Renaudineau (Y)

Immunology department laboratory, Institut Fédératif de Biologie, Toulouse University Hospital Center, France; INFINITy, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM U1291, CNRS U5051, University Toulouse III, Toulouse, France. Electronic address: renaudineau.y@chu-toulouse.fr.

Florence Abravanel (F)

INFINITy, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM U1291, CNRS U5051, University Toulouse III, Toulouse, France; Virology department laboratory, Institut Fédératif de Biologie, Toulouse University Hospital Center, France. Electronic address: abravanel.f@chu-toulouse.fr.

Jacques Izopet (J)

INFINITy, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM U1291, CNRS U5051, University Toulouse III, Toulouse, France; Virology department laboratory, Institut Fédératif de Biologie, Toulouse University Hospital Center, France. Electronic address: izopet.j@chu-toulouse.fr.

Chloé Bost (C)

Immunology department laboratory, Institut Fédératif de Biologie, Toulouse University Hospital Center, France; INFINITy, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM U1291, CNRS U5051, University Toulouse III, Toulouse, France. Electronic address: bost.c@chu-toulouse.fr.

Emmanuel Treiner (E)

Immunology department laboratory, Institut Fédératif de Biologie, Toulouse University Hospital Center, France; INFINITy, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM U1291, CNRS U5051, University Toulouse III, Toulouse, France. Electronic address: treiner.e@chu-toulouse.fr.

Nicolas Congy (N)

Immunology department laboratory, Institut Fédératif de Biologie, Toulouse University Hospital Center, France. Electronic address: congy.n@chu-toulouse.fr.

Antoine Blancher (A)

Immunology department laboratory, Institut Fédératif de Biologie, Toulouse University Hospital Center, France; INFINITy, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM U1291, CNRS U5051, University Toulouse III, Toulouse, France. Electronic address: blancher.antoine@neuf.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH